Guobang Pharma Ltd. (SHA:605507)
China · Delayed Price · Currency is CNY 15.53
-0.17 (-1.08%)
Aug 14, 2026, 3:00 PM CST
Guobang Pharma Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 13, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 11,989 | 13,714 | 11,513 | 9,813 | 14,792 | 16,111 | |
Market Cap Growth | -7.07% | 19.12% | 17.32% | -33.66% | -8.19% | - |
Enterprise Value | 10,504 | 12,467 | 10,267 | 8,306 | 12,684 | 13,589 |
Last Close Price | 15.53 | 17.23 | 14.05 | 11.64 | 17.09 | 18.45 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 13, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 16.96 | 16.71 | 14.73 | 16.02 | 16.06 | 22.82 |
Forward PE | - | 14.81 | 10.92 | 11.33 | 12.98 | - |
PS Ratio | 1.96 | 2.28 | 1.95 | 1.83 | 2.59 | 3.58 |
PB Ratio | 1.43 | 1.60 | 1.43 | 1.32 | 2.07 | 2.54 |
P/TBV Ratio | 1.49 | 1.67 | 1.50 | 1.39 | 2.18 | 2.65 |
P/FCF Ratio | 25.92 | 48.71 | 40.07 | - | 69.15 | - |
P/OCF Ratio | 13.16 | 24.52 | 16.30 | 18.99 | 14.54 | - |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 13, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 1.71 | 2.07 | 1.74 | 1.55 | 2.22 | 3.02 |
EV/EBITDA Ratio | 8.05 | 8.96 | 8.09 | 8.74 | 10.48 | 13.37 |
EV/EBIT Ratio | 12.86 | 13.64 | 12.28 | 13.20 | 13.35 | 16.66 |
EV/FCF Ratio | 22.71 | 44.28 | 35.74 | - | 59.29 | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 13, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.12 | 0.12 | 0.10 | 0.13 | 0.09 | 0.03 |
Debt / EBITDA Ratio | 0.78 | 0.72 | 0.61 | 1.02 | 0.55 | 0.17 |
Debt / FCF Ratio | 2.21 | 3.54 | 2.72 | - | 3.11 | - |
Net Debt / Equity Ratio | -0.18 | -0.20 | -0.22 | -0.21 | -0.30 | -0.31 |
Net Debt / EBITDA Ratio | -1.14 | -1.23 | -1.38 | -1.67 | -1.76 | -1.95 |
Net Debt / FCF Ratio | -3.23 | -6.06 | -6.08 | 6.87 | -9.98 | 3.18 |
Asset Turnover | 0.55 | 0.55 | 0.56 | 0.55 | 0.69 | 0.69 |
Inventory Turnover | 2.78 | 2.86 | 3.26 | 2.98 | 3.08 | 2.79 |
Quick Ratio | 1.41 | 2.15 | 1.54 | 1.45 | 1.93 | 2.40 |
Current Ratio | 2.33 | 3.18 | 2.30 | 2.22 | 2.75 | 3.96 |
Return on Equity (ROE) | 8.56% | 9.85% | 10.08% | 8.36% | 13.64% | 14.68% |
Return on Assets (ROA) | 4.62% | 5.25% | 4.94% | 4.05% | 7.17% | 7.83% |
Return on Invested Capital (ROIC) | 10.21% | 11.95% | 12.09% | 10.13% | 18.00% | 19.50% |
Return on Capital Employed (ROCE) | 9.50% | 10.10% | 10.20% | 8.00% | 13.20% | 12.80% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 13, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 5.89% | 5.99% | 6.79% | 6.24% | 6.23% | 4.38% |
FCF Yield | 3.86% | 2.05% | 2.50% | -2.36% | 1.45% | -3.88% |
Dividend Yield | 2.76% | 2.49% | 3.08% | 1.85% | 2.51% | 2.71% |
Payout Ratio | 50.21% | 43.81% | 24.83% | 59.05% | 13.92% | 47.27% |
Buyback Yield / Dilution | 1.87% | 0.65% | -0.27% | 0.24% | -9.09% | -8.01% |
Total Shareholder Return | 4.63% | 3.14% | 2.81% | 2.09% | -6.58% | -5.30% |